PROBUCOL - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for probucol and what is the scope of patent protection?

Probucol is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for probucol.

Summary for PROBUCOL

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	6
Raw Ingredient (Bulk) Api Vendors:	108
Clinical Trials:	20
Patent Applications:	6,668
DailyMed Link:	PROBUCOL at DailyMed

Recent Clinical Trials for PROBUCOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
General Hospital of Shenyang Military Region	Phase 4
McGill University	Phase 1/Phase 2
Douglas Mental Health University Institute	Phase 1/Phase 2

See all PROBUCOL clinical trials

Medical Subject Heading (MeSH) Categories for PROBUCOL

Anticholesteremic Agents
Antioxidants

Anatomical Therapeutic Chemical (ATC) Classes for PROBUCOL

C10AX	Other lipid modifying agents
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for PROBUCOL

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-002	Jul 6, 1988		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for PROBUCOL

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-002	Jul 6, 1988	⤷ Sign Up	⤷ Sign Up
Sanofi Aventis Us	LORELCO	probucol	TABLET;ORAL	017535-001	Approved Prior to Jan 1, 1982	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.